• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

射血分数保留的心力衰竭中的合并症。

Comorbidities in heart failure with preserved ejection fraction.

机构信息

Medizinische Klinik mit Schwerpunkt Kardiologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK), Augustenburger Platz 1, 13353, Berlin, Germany.

Standort Berlin, DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung), Berlin, Germany.

出版信息

Herz. 2022 Aug;47(4):301-307. doi: 10.1007/s00059-022-05123-9. Epub 2022 Jun 8.

DOI:10.1007/s00059-022-05123-9
PMID:35674774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9355932/
Abstract

Chronic heart failure is one of the most common causes of hospitalization and death in industrialized countries. Demographic changes with an aging population are expected to further increase the prevalence of chronic heart failure. The associated increase in comorbidities in patients with chronic heart failure leads to a less favorable prognosis for survival. A selection of the major comorbidities discussed in this review-along with prevalence, impact on prognosis, treatment approaches, and current study status-include atrial fibrillation, arterial hypertension, coronary artery disease, coronary microvascular dysfunction, renal dysfunction, type 2 diabetes, sleep apnea, reduced lymphatic reserve, and the effects on oxygen utilization and physical activity. The complex clinical picture of heart failure with preserved ejection fraction (HFpEF) remains challenging in the nearly absence of evidence-based therapy. Except for comorbidity-specific guidelines, no HFpEF-specific treatment of comorbidities can be recommended at this time. Optimized care is becoming increasingly relevant to reducing hospitalizations through a seamless inpatient and outpatient care structure. Current treatment is focused on symptom relief and management of associated comorbidities. Therefore, prevention through early minimization of risk factors currently remains the best approach.

摘要

慢性心力衰竭是工业化国家住院和死亡的最常见原因之一。预计人口老龄化带来的人口结构变化将进一步增加慢性心力衰竭的患病率。慢性心力衰竭患者合并症的增加导致其生存预后较差。本综述讨论了一些主要的合并症——包括患病率、对预后的影响、治疗方法和当前的研究状况——如心房颤动、动脉高血压、冠状动脉疾病、冠状动脉微血管功能障碍、肾功能障碍、2 型糖尿病、睡眠呼吸暂停、淋巴储备减少,以及对氧气利用和体力活动的影响。射血分数保留的心力衰竭(HFpEF)的复杂临床情况在几乎没有循证治疗的情况下仍然具有挑战性。除了特定于合并症的指南外,目前不能推荐针对 HFpEF 特定的合并症的治疗方法。通过无缝的住院和门诊护理结构来优化护理,对于减少住院治疗变得越来越重要。目前的治疗重点是缓解症状和管理相关合并症。因此,通过早期最大限度地减少风险因素来预防仍然是最好的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/2701d0a1712a/59_2022_5123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/b937eba51100/59_2022_5123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/6c0ef79818d0/59_2022_5123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/8fd56151489d/59_2022_5123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/2701d0a1712a/59_2022_5123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/b937eba51100/59_2022_5123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/6c0ef79818d0/59_2022_5123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/8fd56151489d/59_2022_5123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/9355932/2701d0a1712a/59_2022_5123_Fig4_HTML.jpg

相似文献

1
Comorbidities in heart failure with preserved ejection fraction.射血分数保留的心力衰竭中的合并症。
Herz. 2022 Aug;47(4):301-307. doi: 10.1007/s00059-022-05123-9. Epub 2022 Jun 8.
2
Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.射血分数保留的心力衰竭的药物治疗和合并症管理进展:来自临床试验的证据
Heart Fail Rev. 2024 Mar;29(2):305-320. doi: 10.1007/s10741-023-10338-x. Epub 2023 Aug 10.
3
Epidemiology of heart failure with preserved ejection fraction.射血分数保留的心力衰竭的流行病学
Curr Heart Fail Rep. 2014 Dec;11(4):354-65. doi: 10.1007/s11897-014-0223-7.
4
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.一种新型射血分数保留心力衰竭模式:合并症通过冠状动脉微血管内皮炎症导致心肌功能障碍和重构。
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15.
5
Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction.射血分数保留的心力衰竭住院患者的特征
Am J Med. 2016 Jun;129(6):635.e15-26. doi: 10.1016/j.amjmed.2016.02.007.
6
Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.射血分数保留的心力衰竭伴发心原性猝死:难以捉摸的靶点。
Heart Fail Rev. 2019 Nov;24(6):847-866. doi: 10.1007/s10741-019-09804-2.
7
Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study.冠状动脉微血管功能障碍与射血分数保留的心力衰竭患者心力衰竭住院和死亡的相关性:PROMIS-HFpEF 研究的随访。
J Card Fail. 2020 Nov;26(11):1016-1021. doi: 10.1016/j.cardfail.2020.08.010. Epub 2020 Aug 23.
8
[Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].[中国实际临床实践中住院心力衰竭患者的当代流行病学与治疗]
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Nov 24;47(11):865-874. doi: 10.3760/cma.j.issn.0253-3758.2019.11.004.
9
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.射血分数降低、中间范围和保留的心衰中的非心脏合并症。
Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.
10
Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭中的凝血障碍和血栓形成并发症
Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102127. doi: 10.1016/j.cpcardiol.2023.102127. Epub 2023 Oct 5.

引用本文的文献

1
Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis.肾去神经支配通过抑制ATP-P2X7-NLRP3炎性小体轴减轻射血分数保留的心力衰竭患者的心脏功能障碍。
Basic Res Cardiol. 2025 Sep 16. doi: 10.1007/s00395-025-01138-5.
2
Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.女性射血分数保留的心力衰竭的基础——从预防到改善功能。与《美国预防心脏病学杂志》和《心力衰竭杂志》合作出版。
Am J Prev Cardiol. 2025 Feb 19;23:100928. doi: 10.1016/j.ajpc.2025.100928. eCollection 2025 Sep.
3

本文引用的文献

1
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.射血分数轻度降低和保留的心力衰竭患者的基线特征:DELIVER试验
JACC Heart Fail. 2022 Mar;10(3):184-197. doi: 10.1016/j.jchf.2021.11.006.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.2021 ESC 急性和慢性心力衰竭诊断和治疗指南:由欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断和治疗工作组制定。特别感谢欧洲心脏病学会心力衰竭协会(HFA)的贡献。
Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333.
3
Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation.
针对射血分数保留的心力衰竭中的心房颤动:脉冲场消融的新作用
Front Physiol. 2025 Jul 30;16:1621118. doi: 10.3389/fphys.2025.1621118. eCollection 2025.
4
Identifying and characterizing commercially insured patients with HFpEF with high vs low health care resource utilization.识别和描述高医疗资源利用率与低医疗资源利用率的射血分数保留的心力衰竭商业保险患者。
J Manag Care Spec Pharm. 2025 Aug;31(8):741-751. doi: 10.18553/jmcp.2025.31.8.741.
5
Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis.探究钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留的心力衰竭(HFmrEF)和射血分数正常的心力衰竭(HFpEF)患者心血管相关健康状况的影响:系统评价与荟萃分析
Front Cardiovasc Med. 2025 Jul 4;12:1556606. doi: 10.3389/fcvm.2025.1556606. eCollection 2025.
6
Heart failure treatment patterns: A pharmacoepidemiological descriptive study in Colombia (The HEATCO study).心力衰竭治疗模式:哥伦比亚的一项药物流行病学描述性研究(HEATCO研究)
PLoS One. 2025 Jun 24;20(6):e0325515. doi: 10.1371/journal.pone.0325515. eCollection 2025.
7
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.心力衰竭中的心脏中间代谢:底物利用、信号作用及治疗靶点。
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01166-7.
8
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos.心力衰竭中的心血管、肾脏、肝脏及代谢相互作用:打破壁垒
Circ Res. 2025 May 23;136(11):1170-1207. doi: 10.1161/CIRCRESAHA.125.325602. Epub 2025 May 22.
9
Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis.将心脏代谢疾病与射血分数保留的心力衰竭相联系的循环介质:一项中介孟德尔随机化分析
Cardiovasc Diabetol. 2025 May 12;24(1):201. doi: 10.1186/s12933-025-02738-0.
10
Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions.衰弱与心力衰竭:临床见解、患者预后及未来方向。
Card Fail Rev. 2025 Feb 26;11:e05. doi: 10.15420/cfr.2024.34. eCollection 2025.
NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.NT-proBNP 作为四项观察性门诊试验中房颤和心力衰竭的标志物。
ESC Heart Fail. 2022 Feb;9(1):100-109. doi: 10.1002/ehf2.13703. Epub 2021 Nov 30.
4
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.勘误:《2021欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗指南》:由欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组制定,并得到了ESC心力衰竭协会(HFA)的特别贡献。
Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670.
5
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
6
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.达格列净治疗射血分数保留和轻度降低的心衰:DELIVER 试验的原理和设计。
Eur J Heart Fail. 2021 Jul;23(7):1217-1225. doi: 10.1002/ejhf.2249. Epub 2021 Jun 9.
7
Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot.心力衰竭患者心房颤动的导管消融:解开戈尔迪之结
J Geriatr Cardiol. 2021 Apr 28;18(4):297-306. doi: 10.11909/j.issn.1671-5411.2021.04.002.
8
Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification.心力衰竭住院治疗:统一 30 年后东德和西德仍存在显著差异。
ESC Heart Fail. 2021 Aug;8(4):2546-2555. doi: 10.1002/ehf2.13407. Epub 2021 May 4.
9
Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide.导管消融治疗射血分数保留的心力衰竭伴非阵发性心房颤动:对功能和 B 型利钠肽的可行性和益处。
Europace. 2021 Aug 6;23(8):1252-1261. doi: 10.1093/europace/euaa420.
10
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.一项前瞻性研究,使用侵入性血液动力学测量来评估房颤和早期射血分数保留心衰(HFpEF)患者导管消融术后的情况:STALL AF-HFpEF。
Eur J Heart Fail. 2021 May;23(5):785-796. doi: 10.1002/ejhf.2122. Epub 2021 Mar 8.